AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21063203 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 28
Study 21063203 — intervention group
Group type: COMPARATOR
Intervention: Calcium channel blocker (general)
Number of subjects: 28
Study 21063203 — intervention group
Group type: COMPARATOR
Intervention: Untreated hypertensive patients
Number of subjects: 28
Study 19884620 — intervention group
Group type: EXPERIMENTAL
Intervention: Family‐based home health education (HHE) from lay health workers every 3 months and annual training of general practitioners (GPs) in hypertension management
Number of subjects: 1341
Study 19884620 — intervention group
Group type: COMPARATOR
Intervention: GP‐only, HHE‐only, or no intervention
Number of subjects: 1341
Study 17324670 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-protein-rich diet (15 g soy protein/1,000 kcal daily)
Number of subjects: 47
Study 17324670 — intervention group
Group type: COMPARATOR
Intervention: Control diet (caloric intake decreased by 500 kcal/day)
Number of subjects: 47
Study 17324670 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-protein-rich diet
Number of subjects: 47
Study 17324670 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 47
Study 16902384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education intervention conducted by a dietician during two half‐day sessions.
Number of subjects: 236
Study 16902384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 236
Study 16902384 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional education intervention.
Number of subjects: 236
Study 15279619 — intervention group
Group type: EXPERIMENTAL
Intervention: B-group vitamin supplementation (5 mg of folate, 5 mg of vitamin B2, 50 mg of vitamin B6, 0.4 mg of vitamin B12) for 14 days
Number of subjects: 48
Study 15279619 — intervention group
Group type: EXPERIMENTAL
Intervention: B-group vitamin supplementation
Number of subjects: 48
Study 15279619 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplements)
Number of subjects: 48
Study 15279619 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 10939701 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine (500 microg in 1 ml volume)
Number of subjects: 40
Study 10939701 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 ml saline)
Number of subjects: 40
Study 9411412 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients
Number of subjects: 100
Study 9411412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 1286502 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.67 mg IV, range 0.2 to 1 mg)
Number of subjects: 139
Study 1286502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 1286502 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 139
Study 3885203 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg daily
Number of subjects: 31
Study 3885203 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol 200 mg daily
Number of subjects: 31
Study 29241423 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconsolidation of Traumatic Memories (RTM)
Number of subjects: 74
Study 29045324 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's Health Activity Motor Program (CHAMP; n = 81)
Number of subjects: 124
Study 29045324 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 43)
Number of subjects: 124
Study 25733342 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and weight loss self-efficacy
Number of subjects: 1285
Study 25733342 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly fruit consumption, past weight loss experience, and weight loss self-efficacy
Number of subjects: 1285
Study 23904292 — intervention group
Group type: EXPERIMENTAL
Intervention: gE combined with AS01B
Number of subjects: 100
Study 23904292 — intervention group
Group type: EXPERIMENTAL
Intervention: gE combined with AS01E
Number of subjects: 100
Study 23904292 — intervention group
Group type: COMPARATOR
Intervention: unadjuvanted gE
Number of subjects: 100
Study 23904292 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 100
Study 21916532 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured self-monitoring of blood glucose (SMBG) protocol
Number of subjects: 483
Study 21916532 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 483
Study 19154823 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mouse units (MU)/mL dilution, 0.4cc/site, 4-quadrant injection
Number of subjects: 21
Study 19154823 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 MU/mL dilution, 0.4cc/site, 4 sites along endplate band
Number of subjects: 21
Study 19154823 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 MU/mL dilution, 2cc/site, 4-quadrant injection
Number of subjects: 21
Study 19154823 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 17005059 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hygroscopic heat-and-moisture exchanger (HME) with 15-cm flexible tubing
Number of subjects: 7
Study 17005059 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-cm flexible tubing only
Number of subjects: 7
Study 17005059 — intervention group
Group type: EXPERIMENTAL
Intervention: No HME or flexible tubing
Number of subjects: 7
Study 15510460 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified needle drainage (MND)
Number of subjects: 80
Study 15510460 — intervention group
Group type: COMPARATOR
Intervention: Conventional drainage (CD)
Number of subjects: 80
Study 11157183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 30 mg QID for 10 days
Number of subjects: 454
Study 11157183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 454
Study 9633738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (210 mg/day)
Number of subjects: 131
Study 9633738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 9633738 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 131
Study 7833494 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 248
Study 7833494 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 248
Study 7833494 — intervention group
Group type: COMPARATOR
Intervention: Chlorpropamide
Number of subjects: 248
Study 7833494 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 248
Study 7833494 — intervention group
Group type: COMPARATOR
Intervention: Gliquidone
Number of subjects: 248
Study 2979230 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid
Number of subjects: 40
Study 2979230 — intervention group
Group type: COMPARATOR
Intervention: acetyl-5-aminosalicylic acid
Number of subjects: 40
Study 30760305 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral system for a brief intervention titled 'self-confidence'
Number of subjects: 459
Study 30760305 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral system for a brief intervention
Number of subjects: 459
Study 30760305 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-referral to a brief intervention for depression
Number of subjects: 459
Study 28238058 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia training
Number of subjects: 70
Study 28238058 — intervention group
Group type: EXPERIMENTAL
Intervention: Practical training
Number of subjects: 70
Study 28238058 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 70
Study 25573751 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (dosage not specified)
Number of subjects: 220
Study 25573751 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin pharmacokinetics in GT genotype
Number of subjects: 220
Study 25573751 — intervention group
Group type: COMPARATOR
Intervention: Metformin pharmacokinetics in GG genotype
Number of subjects: 220
Study 22244715 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-normal systolic blood pressure (<120 mm Hg)
Number of subjects: 3680
Study 22244715 — intervention group
Group type: COMPARATOR
Intervention: High-normal systolic blood pressure (120 to <140 mm Hg)
Number of subjects: 3680
Study 22244715 — intervention group
Group type: EXPERIMENTAL
Intervention: High systolic blood pressure (>140 mm Hg)
Number of subjects: 3680
Study 21691762 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 50
Study 21691762 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia
Number of subjects: 50
Study 19061721 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of autologous bone marrow mononuclear cells
Number of subjects: 115
Study 16487195 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG‐IUS
Number of subjects: 79
Study 16487195 — intervention group
Group type: COMPARATOR
Intervention: Thermal balloon ablation
Number of subjects: 79
Study 16487195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 79
Study 15537429 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-warning letter
Number of subjects: 627
Study 15537429 — intervention group
Group type: COMPARATOR
Intervention: No pre-warning letter
Number of subjects: 627
Study 11027869 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRI
Number of subjects: 500
Study 11027869 — intervention group
Group type: COMPARATOR
Intervention: Two-view x-ray mammography
Number of subjects: 500
Study 11027869 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI examination
Number of subjects: 500
Study 11027869 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric analysis
Number of subjects: 500
Study 11027869 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis
Number of subjects: 500
Study 11027869 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall diagnostic performance
Number of subjects: 500
Study 9174449 — intervention group
Group type: EXPERIMENTAL
Intervention: High-vacuum drains
Number of subjects: 73
Study 9174449 — intervention group
Group type: COMPARATOR
Intervention: Low-vacuum drains
Number of subjects: 73
Study 1443704 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1.5 mg/kg
Number of subjects: 150
Study 1443704 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 150
Study 1443704 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (all doses)
Number of subjects: 150
Study 1443704 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (larger doses)
Number of subjects: 150
Study 1443704 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms/kg before propofol
Number of subjects: 150
Study 2951797 — intervention group
Group type: EXPERIMENTAL
Intervention: Duovent (100 micrograms fenoterol and 40 micrograms ipratropium bromide per puff)
Number of subjects: 18
Study 2951797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 31992758 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in HDL-C by 10 mg/dL from preconception to 28 weeks
Number of subjects: 575
Study 31992758 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in TG by 10 mg/dL from preconception to 28 weeks
Number of subjects: 575
Study 31992758 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in HDL-C by 10 mg/dL from preconception to 28 weeks (for BMI ≥25)
Number of subjects: 575
Study 29454039 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 µg selenium/d as selenium-enriched-yeast
Number of subjects: 491
Study 29454039 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg selenium/d as selenium-enriched-yeast
Number of subjects: 491
Study 29454039 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg selenium/d as selenium-enriched-yeast
Number of subjects: 491
Study 29454039 — intervention group
Group type: COMPARATOR
Intervention: Placebo-yeast
Number of subjects: 491
Study 29231404 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with rehabilitation
Number of subjects: 98
Study 29231404 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation only
Number of subjects: 98
Study 23636469 — intervention group
Group type: EXPERIMENTAL
Intervention: isocaloric AGE‐restricted diet (<10 AGE Eq/day) for 4 months
Number of subjects: 85
Study 23636469 — intervention group
Group type: COMPARATOR
Intervention: standard diet (regular >15 AGE Eq/day)
Number of subjects: 85
Study 23636469 — intervention group
Group type: EXPERIMENTAL
Intervention: Model AGEs in WT cells
Number of subjects: 85
Study 23636469 — intervention group
Group type: EXPERIMENTAL
Intervention: Model AGEs in AGER1(+) cells
Number of subjects: 85
Study 23388205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-biopsy educational (ED) packet containing biopsy instruction sheet and a booklet about the biopsy procedure and prostate cancer treatment decision aid
Number of subjects: 29
Study 23388205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-biopsy educational (ED) packet
Number of subjects: 29
Study 23388205 — intervention group
Group type: COMPARATOR
Intervention: Men diagnosed with cancer in the UC group
Number of subjects: 29
Study 19968611 — intervention group
Group type: EXPERIMENTAL
Intervention: Geranylgeranylacetone (GGA) 150 mg/day
Number of subjects: 20
Study 19968611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 18334144 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Capsule (3 capsules three times a day)
Number of subjects: 114
Study 18334144 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanxit (10.5 mg twice daily)
Number of subjects: 114
Study 18334144 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling Capsule plus Deanxit (both treatments)
Number of subjects: 114
Study 18334144 — intervention group
Group type: COMPARATOR
Intervention: Wuling Capsule
Number of subjects: 114
Study 18334144 — intervention group
Group type: COMPARATOR
Intervention: Deanxit
Number of subjects: 114
Study 16799817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking (NW)
Number of subjects: 15
Study 16799817 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (W)
Number of subjects: 15
Study 16799817 — intervention group
Group type: EXPERIMENTAL
Intervention: Jogging (J)
Number of subjects: 15
Study 12749506 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-K 12.5 mg
Number of subjects: 356
Study 12749506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 356
Study 12749506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study 11066466 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based motivational interviewing sessions (median of four sessions)
Number of subjects: 100
Study 11066466 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine smoking guidance)
Number of subjects: 100
Study 11066466 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based motivational interviewing sessions
Number of subjects: 100
Study 11066466 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal telephone questionnaire
Number of subjects: 100
Study 9264092 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beverages consumed ad lib prior to testing
Number of subjects: 24
Study 9264092 — intervention group
Group type: COMPARATOR
Intervention: Caffeine abstinence
Number of subjects: 24
Study 8473428 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy (n = 10)
Number of subjects: 18
Study 8473428 — intervention group
Group type: COMPARATOR
Intervention: No therapy (n = 8)
Number of subjects: 18
Study 3784284 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (30 to 80 mEq/day, usually 60 mEq/day)
Number of subjects: 18
Study 3784284 — intervention group
Group type: COMPARATOR
Intervention: Sodium alkali (as bicarbonate or citrate, 60 to 118 mEq/day)
Number of subjects: 18
Study 30371283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C (Cys-C)
Number of subjects: 4965
Study 27043416 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=305)
Number of subjects: 901
Study 27043416 — intervention group
Group type: EXPERIMENTAL
Intervention: NBS group (n=300)
Number of subjects: 901
Study 27043416 — intervention group
Group type: EXPERIMENTAL
Intervention: NBS + DBS group (n=296)
Number of subjects: 901
Study 24633934 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 (240 mg daily for 24 weeks)
Number of subjects: 160
Study 24633934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 24633934 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761
Number of subjects: 160
Study 23612435 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 77
Study 23612435 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (Suboxone)
Number of subjects: 77
Study 21097765 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline implementation strategies (reminders, educational outreach, audit and feedback)
Number of subjects: 0
Study 21097765 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored guideline implementation strategies
Number of subjects: 0
Study 21097765 — intervention group
Group type: COMPARATOR
Intervention: Standard guideline implementation strategies
Number of subjects: 0
Study 18004064 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. administered once every 2 weeks (Q2W) via subcutaneous or intravenous injection
Number of subjects: 336
Study 18004064 — intervention group
Group type: COMPARATOR
Intervention: Epoetin administered at current dose, route, and administration interval (once to three times weekly)
Number of subjects: 336
Study 16488335 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 1347
Study 16488335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1347
Study 14696659 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ implants
Number of subjects: 425
Study 14696659 — intervention group
Group type: COMPARATOR
Intervention: TPS implants
Number of subjects: 425
Study 12422907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin for 7 days
Number of subjects: 71
Study 12422907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 10636336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic/pharmacodynamic (PK/PD) modelling
Number of subjects: 0
Study 7724390 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (digoxin, furosemide, low dose ACE inhibition)
Number of subjects: 236
Study 7724390 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged therapy (maximal tolerated ACE inhibition, PGE1 therapy, outpatient dobutamine)
Number of subjects: 236
Study 1837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (CFZ)
Number of subjects: 111
Study 1837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (CFN)
Number of subjects: 111
Study 1837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectinomycin (SPM)
Number of subjects: 111
Study 1837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (AZT)
Number of subjects: 111
Study 1837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (PP)
Number of subjects: 111
Study 1837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (DXC)
Number of subjects: 111
Study 1837942 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated treatment (C3)
Number of subjects: 111
Study 7107969 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol, maximum dose 140 mg per week
Number of subjects: 59
Study 7107969 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine, maximum dose 7350 mg per week
Number of subjects: 59
Study 3830763 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day (D240)
Number of subjects: 16
Study 3830763 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day (D360)
Number of subjects: 16
Study 3830763 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 120 mg/day (N)
Number of subjects: 16
Study 3830763 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 480 mg/day (V)
Number of subjects: 16
Study 29287633 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritative feeding styles in low risk families
Number of subjects: 626
Study 29287633 — intervention group
Group type: EXPERIMENTAL
Intervention: Authoritative feeding styles in poor, food insecure, and depressed families
Number of subjects: 626
Study 29287633 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninvolved feeding styles in poor, food insecure, and depressed families
Number of subjects: 626
Study 26791678 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 0.5 mg kg(‐1) day(‐1) for 10 days
Number of subjects: 31
Study 26791678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 25623842 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and therapy-related factors (age, gender, bruxism, number of prostheses, time since last extraction, smoking, fit of dentures, average denture wearing time, wearing during the night)
Number of subjects: 89
Study 23623998 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle modification programme
Number of subjects: 154
Study 23623998 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 154
Study 19934621 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention intervention
Number of subjects: 392
Study 19934621 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 392
Study 18375896 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (1 mg) for 3 months
Number of subjects: 54
Study 18375896 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg) for 3 months
Number of subjects: 54
Study 16683008 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin combined with ExMI therapy (group 2)
Number of subjects: 40
Study 16683008 — intervention group
Group type: COMPARATOR
Intervention: Terazosin monotherapy (group 1)
Number of subjects: 40
Study 14756928 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) analgesia during physiotherapy sessions
Number of subjects: 1
Study 14756928 — intervention group
Group type: COMPARATOR
Intervention: No Virtual Reality (no-VR) condition during physiotherapy sessions
Number of subjects: 1